Indeglitazar
- Product Name
- Indeglitazar
- CAS No.
- 835619-41-5
- Chemical Name
- Indeglitazar
- Synonyms
- PPM 204;Indeglitazar;Inde litazar;Indeglitazar, 10 mM in DMSO;Indeglitazar (PPM 204 and PLX 204);5-Methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indole-3-propanoic acid;1H-Indole-3-propanoic acid, 5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-;3-(5-Methoxy-1-((4-methoxyphenyl)sulfonyl)-1H-indol-3-yl)propanoic acid
- CBNumber
- CB22627977
- Molecular Formula
- C19H19NO6S
- Formula Weight
- 389.42
- MOL File
- 835619-41-5.mol
Indeglitazar Property
- Boiling point:
- 625.3±65.0 °C(Predicted)
- Density
- 1.34±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMSO:100.0(Max Conc. mg/mL);256.79(Max Conc. mM)
- form
- Solid
- pka
- 4.49±0.10(Predicted)
- color
- White to gray
N-Bromosuccinimide Price
- Product number
- CS-6601
- Product name
- Indeglitazar
- Purity
- 99.59%
- Packaging
- 5mg
- Price
- $80
- Updated
- 2021/12/16
- Product number
- CS-6601
- Product name
- Indeglitazar
- Purity
- 99.59%
- Packaging
- 25mg
- Price
- $200
- Updated
- 2021/12/16
- Product number
- CS-6601
- Product name
- Indeglitazar
- Purity
- 99.59%
- Packaging
- 50mg
- Price
- $300
- Updated
- 2021/12/16
- Product number
- CS-6601
- Product name
- Indeglitazar
- Purity
- 99.59%
- Packaging
- 100mg
- Price
- $450
- Updated
- 2021/12/16
- Product number
- API0013948
- Product name
- INDEGLITAZAR
- Purity
- 95.00%
- Packaging
- 5MG
- Price
- $498.3
- Updated
- 2021/12/16
Indeglitazar Chemical Properties,Usage,Production
Uses
Indeglitazar (PPM 204) is an orally available PPAR pan-agonist for all three PPARα, PPARδ and PPARγ[1].
in vivo
An initial assessment of in vivo activity is carried out using the Zucker rat model of diabetes. The significant lowering of glucose, HbA1C, triglycerides, and total cholesterol are observed after i.v. treatment with 10 mg/kg Indeglitazar once per day for 3 weeks. Notably, the level of Adiponectin (on day 21) is essentially unchanged in treated vs. untreated animals (4.8 mcg/mL vs. 4.9 mcg/mL), thus the observed reductions in glucose and HbA1C are achieved in an adiponectin-independent fashion. These differences in the effects of Indeglitazar in vivo may be a consequence of synergy between the 3 PPAR activities or because of the SPPARM profile of the compound, or a combination of these factors. The oral activity of Indeglitazar is assessed in the ob/ob model of diabetes and insulin resistance. Indeglitazar significantly decreases glucose, insulin, triglycerides, and free fatty acid levels[1].
IC 50
PPARα; PPARδ; PPARγ
References
[1] Artis DR, et al. Scaffold-based discovery of Indeglitazar, a PPAR pan-active anti-diabetic agent. Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):262-7. DOI:10.1073/pnas.0811325106